HomeTrialNCT06608927
🔬NCT06608927Phase 3ACTIVE NOT RECRUITING

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Study Summary

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

View on ClinicalTrials.gov ↗
Study Details
Enrollment610 participants
Primary Completion
Lead SponsorArcus Biosciences, Inc.
Data Retrieved2026-04-11 02:54:25.662861+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.